Rice bran extract attenuates cognitive impairment by enhancing pancreatic β-cell insulin secretion in STZ-induced

Madonna Magdy Youssef1, Mohammed Farrag El-Yamany2, Reham Mahmoud Abdel-Kader3

  • 1Pharmacovigilance Department, Egyptian Drug Authority, Giza, Egypt. Madonna.magdy@std.pharma.cu.edu.eg.

PubMed

Insights

Egyptian RB ethanol extract (RBE) may improve Type I diabetes by boosting insulin secretion and restoring cognitive function in rats. This PPARγ activator shows promise for reversing diabetic complications and enhancing memory.

Area of Science:

  • Endocrinology
  • Neuroscience
  • Pharmacology

Background:

  • Type I diabetes (T1D) involves pancreatic beta-cell destruction, leading to cognitive impairments.
  • Current insulin therapy has limitations, and restoring beta-cell function is a therapeutic goal.
  • Peroxisome proliferator-activated receptor gamma (PPARγ) agonists may restore beta-cell biology.

Purpose of the Study:

  • To investigate the molecular mechanism of Egyptian RB ethanol extract (RBE) in glucose-stimulated insulin secretion and beta-cell function restoration.
  • To evaluate RBE's impact on cognitive function in a diabetic rat model.

Main Methods:

  • A streptozotocin (STZ)-induced diabetic rat model was used with five treatment groups.
  • Rats were treated daily with RBE or insulin for 21 days.
  • Biochemical parameters, gene expression (PPAR/PDX1 pathway), cognitive behavior (Y-maze, NOR), and histology were assessed.

Main Results:

  • RBE treatment normalized blood glucose, Glut2, Ca2+, and insulin levels in diabetic rats.
  • Pancreatic insulin levels significantly increased with RBE compared to insulin treatment.
  • RBE upregulated PPARγ, SERCA, and PrKC gene expression (excluding PDX1) and restored cognitive functions.

Conclusions:

  • RBE demonstrates antidiabetic effects by enhancing insulin secretion and restoring beta-cell function.
  • RBE may improve memory and cognition by modulating peripheral insulin secretion via PPARγ activation.

Related Concept Videos

Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
14.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435